Previous studies have shown that CMTM6 can be used as a key regulator of PD-L1 in a variety of tumor cells, binds to PD-L1 and maintains its stable expression of the cell surface, and does not make PD-L1 lysosome-mediated degradation target [13, 14]. This evidence concerns the gene CD274 and neoplasm.